HARMONY BIOSCIENCES HOLDINGS (HRMY)       52.74  +1.97 (+3.88%)

Company Profile

Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical company, which engages in the development and commercialization of therapies for the treatment of neurological disorders. The company is headquartered in Plymouth Meeting, Pennsylvania and currently employs 180 full-time employees. The company went IPO on 2020-08-19. The Company’s operations are conducted through its wholly owned subsidiary, Harmony Biosciences, LLC (Harmony). The firm is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients with neurological disorders. The firm's product WAKIX (pitolisant), is a molecule with a novel mechanism of action (MOA) specifically designed to increase histamine signaling in the brain by binding to H3 receptors. WAKIX is developed for the treatment of excessive daytime sleepiness (EDS) or cataplexy in adult patients with narcolepsy and is the narcolepsy treatment that works primarily through histamine, which is a neurotransmitter. The firm also provides HBS-102, an investigational compound, is a melanin-concentrating hormone (MCH) receptor 1(MCHR1) antagonist that targets MCH neurons in the brain.

Company Info

HARMONY BIOSCIENCES HOLDINGS

630 W Germantown Pike, Suite 215

Plymouth Meeting PENNSYLVANIA 19462

P: 14845399800.0

CEO: John C. Jacobs

Employees: 180

Website: https://www.harmonybiosciences.com/